AMLX

Amylyx Pharmaceuticals, Inc.

A biopharmaceutical company that develops treatments for neurodegenerative diseases, founded in 2013 by two Brown University undergraduates, Joshua Cohen and Justin Klee. Their first drug, Relyvrio (sold as Albrioza in Canada), was approved in 2022 for ALS—the disease that gives the company its name, since "Amy" comes from "amyotrophic" and "lyx" nods to the breakdown of cells the drug targets. The company withdrew Relyvrio from the market in 2024 after a trial showed no clear benefit, though it kept the drug available free to patients already taking it.

CUSIP: 03237H101HealthcareUS1 holder

Ownership Activity Financials Filings

AMLX

AMLX

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Other Events

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition